The development and use of Janus kinase 2 inhibitors for the treatment of myeloproliferative neoplasms
GS Hobbs, S Rozelle, A Mullally - Hematology/Oncology …, 2017 - hemonc.theclinics.com
The discovery of the JAK2V617F mutation in patients with myeloproliferative neoplasms
(MPNs) launched a new era of rationally designed molecularly targeted therapy in BCR-ABL
negative MPN. The JAK2V617F mutation, which activates Janus kinase (JAK)-2 signaling, is
present in more than 95% of patients with polycythemia vera (PV), approximately 65% of
patients with myelofibrosis (MF), and 55% of patients with essential thrombocythemia (ET). 1
Improved understanding of the molecular biology of MPN has established activated JAK …
(MPNs) launched a new era of rationally designed molecularly targeted therapy in BCR-ABL
negative MPN. The JAK2V617F mutation, which activates Janus kinase (JAK)-2 signaling, is
present in more than 95% of patients with polycythemia vera (PV), approximately 65% of
patients with myelofibrosis (MF), and 55% of patients with essential thrombocythemia (ET). 1
Improved understanding of the molecular biology of MPN has established activated JAK …